Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

Similar articles for PubMed (Select 24688052)

1.

KRAS mutation status is associated with enhanced dependency on folate metabolism pathways in non-small cell lung cancer cells.

Moran DM, Trusk PB, Pry K, Paz K, Sidransky D, Bacus SS.

Mol Cancer Ther. 2014 Jun;13(6):1611-24. doi: 10.1158/1535-7163.MCT-13-0649. Epub 2014 Mar 31.

PMID:
24688052
2.

Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.

Sunaga N, Shames DS, Girard L, Peyton M, Larsen JE, Imai H, Soh J, Sato M, Yanagitani N, Kaira K, Xie Y, Gazdar AF, Mori M, Minna JD.

Mol Cancer Ther. 2011 Feb;10(2):336-46. doi: 10.1158/1535-7163.MCT-10-0750.

3.

Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.

Sunaga N, Kaira K, Imai H, Shimizu K, Nakano T, Shames DS, Girard L, Soh J, Sato M, Iwasaki Y, Ishizuka T, Gazdar AF, Minna JD, Mori M.

Oncogene. 2013 Aug 22;32(34):4034-42. doi: 10.1038/onc.2012.402. Epub 2012 Sep 10.

PMID:
22964644
4.

Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.

Chen J, Bi H, Hou J, Zhang X, Zhang C, Yue L, Wen X, Liu D, Shi H, Yuan J, Liu J, Liu B.

Cell Death Dis. 2013 Sep 26;4:e814. doi: 10.1038/cddis.2013.312.

5.

Contributions of KRAS and RAL in non-small-cell lung cancer growth and progression.

Guin S, Ru Y, Wynes MW, Mishra R, Lu X, Owens C, Barn AE, Vasu VT, Hirsch FR, Kern JA, Theodorescu D.

J Thorac Oncol. 2013 Dec;8(12):1492-501. doi: 10.1097/JTO.0000000000000007.

6.

Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer.

Sunaga N, Imai H, Shimizu K, Shames DS, Kakegawa S, Girard L, Sato M, Kaira K, Ishizuka T, Gazdar AF, Minna JD, Mori M.

Int J Cancer. 2012 Apr 15;130(8):1733-44. doi: 10.1002/ijc.26164. Epub 2011 Aug 3.

7.

Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.

Shimamura T, Chen Z, Soucheray M, Carretero J, Kikuchi E, Tchaicha JH, Gao Y, Cheng KA, Cohoon TJ, Qi J, Akbay E, Kimmelman AC, Kung AL, Bradner JE, Wong KK.

Clin Cancer Res. 2013 Nov 15;19(22):6183-92. doi: 10.1158/1078-0432.CCR-12-3904. Epub 2013 Sep 17.

8.

Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies.

Zhang XC, Zhang J, Li M, Huang XS, Yang XN, Zhong WZ, Xie L, Zhang L, Zhou M, Gavine P, Su X, Zheng L, Zhu G, Zhan P, Ji Q, Wu YL.

J Transl Med. 2013 Jul 10;11:168. doi: 10.1186/1479-5876-11-168.

9.

Synthetic lethal therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA delivery.

Mao CQ, Xiong MH, Liu Y, Shen S, Du XJ, Yang XZ, Dou S, Zhang PZ, Wang J.

Mol Ther. 2014 May;22(5):964-73. doi: 10.1038/mt.2014.18. Epub 2014 Feb 5.

10.

Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.

Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G.

J Natl Cancer Inst. 2012 Feb 8;104(3):228-39. doi: 10.1093/jnci/djr523. Epub 2012 Jan 13.

11.

Bosutinib inhibits migration and invasion via ACK1 in KRAS mutant non-small cell lung cancer.

Tan DS, Haaland B, Gan JM, Tham SC, Sinha I, Tan EH, Lim KH, Takano A, Krisna SS, Thu MM, Liew HP, Ullrich A, Lim WT, Chua BT.

Mol Cancer. 2014 Jan 24;13:13. doi: 10.1186/1476-4598-13-13.

12.

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.

Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, Li C, Wheeler DL.

Oncogene. 2011 Feb 3;30(5):561-74. doi: 10.1038/onc.2010.430. Epub 2010 Oct 18.

13.

Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer.

Molina-Arcas M, Hancock DC, Sheridan C, Kumar MS, Downward J.

Cancer Discov. 2013 May;3(5):548-63. doi: 10.1158/2159-8290.CD-12-0446. Epub 2013 Mar 1.

14.

High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation.

Nunez MI, Behrens C, Woods DM, Lin H, Suraokar M, Kadara H, Hofstetter W, Kalhor N, Lee JJ, Franklin W, Stewart DJ, Wistuba II.

J Thorac Oncol. 2012 May;7(5):833-40. doi: 10.1097/JTO.0b013e31824de09c. Erratum in: J Thorac Oncol. 2012 Jun;7(6):1065.

15.

GATA2 is epigenetically repressed in human and mouse lung tumors and is not requisite for survival of KRAS mutant lung cancer.

Tessema M, Yingling CM, Snider AM, Do K, Juri DE, Picchi MA, Zhang X, Liu Y, Leng S, Tellez CS, Belinsky SA.

J Thorac Oncol. 2014 Jun;9(6):784-93. doi: 10.1097/JTO.0000000000000165.

PMID:
24807155
16.

The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer.

Kumar MS, Hancock DC, Molina-Arcas M, Steckel M, East P, Diefenbacher M, Armenteros-Monterroso E, Lassailly F, Matthews N, Nye E, Stamp G, Behrens A, Downward J.

Cell. 2012 Apr 27;149(3):642-55. doi: 10.1016/j.cell.2012.02.059.

17.

Differential expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues.

Liang H, Zhang J, Shao C, Zhao L, Xu W, Sutherland LC, Wang K.

J Exp Clin Cancer Res. 2012 Apr 26;31:36. doi: 10.1186/1756-9966-31-36.

18.

EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation.

Wang M, Kern AM, Hülskötter M, Greninger P, Singh A, Pan Y, Chowdhury D, Krause M, Baumann M, Benes CH, Efstathiou JA, Settleman J, Willers H.

Cancer Res. 2014 May 15;74(10):2825-34. doi: 10.1158/0008-5472.CAN-13-3157. Epub 2014 Mar 19.

19.

Oncogenic KRAS confers chemoresistance by upregulating NRF2.

Tao S, Wang S, Moghaddam SJ, Ooi A, Chapman E, Wong PK, Zhang DD.

Cancer Res. 2014 Dec 15;74(24):7430-41. doi: 10.1158/0008-5472.CAN-14-1439. Epub 2014 Oct 22.

PMID:
25339352
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk